{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:43:42Z","timestamp":1791755022064,"version":"4.3.4"},"reference-count":38,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>To evaluate the efficacy of antivascular endothelial growth factor (anti-VEGF) agents pretreatment before vitrectomy for patients with complicated proliferative diabetic retinopathy (PDR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched up to June 2017 to identify related studies. The Peferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. The StataSE V.12.0 software was used to analyse the relevant data. The weighted mean difference, relative risk and their 95% CIs were used to assess the strength of the association.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>14 randomised controlled trials involving 613 patients were assessed, the anti-VEGF pretreatment group included 289 patients and the control group included 324 patients. Our analysis indicated that anti-VEGF pretreatment before vitrectomy for complicated PDR could facilitate much easier surgery regarding less intraoperative bleeding, less endodiathermy, shorter duration of surgery, less iatrogenic retinal breaks, less frequency of using silicone oil and relaxing retinotomy (P&lt;0.05). Additionally, anti-VEGF pretreatment could also achieve better postoperative best-corrected visual acuity, less early recurrent vitreous haemorrhage (VH) and quicker absorption of recurrent VH (P&lt;0.05). However, the incidence of late recurrent VH, recurrent retinal detachment or related secondary surgery could not be reduced (P&gt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The pretreatment of anti-VEGF agents before vitrectomy for patients with complicated PDR might facilitate much easier surgery and better visual rehabilitation, reduce the rate of early recurrent VH and accelerate its absorption. Moreover, future better-designed studies with larger sample sizes are required to further evaluate the efficacy of different anti-VEGF agents and reach a firmer conclusion.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311344","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T17:16:45Z","timestamp":1513358205000},"page":"1077-1085","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":65,"title":["Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"102","author":[{"given":"Xin-yu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"2020050713014887000_102.8.1077.1","doi-asserted-by":"publisher","DOI":"10.1080\/09286580701396720"},{"key":"2020050713014887000_102.8.1077.2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/112067210901900114","article-title":"Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing eye study","volume":"19","author":"Xie","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"2020050713014887000_102.8.1077.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34015-0"},{"key":"2020050713014887000_102.8.1077.4","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"2020050713014887000_102.8.1077.5","first-page":"1","article-title":"A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy","volume":"2016","author":"Yang","year":"2016","journal-title":"J Ophthalmol"},{"key":"2020050713014887000_102.8.1077.6","first-page":"865","article-title":"Postvitrectomy diabetic vitreous hemorrhage in proliferative diabetic retinopathy","volume":"17","author":"Shi","year":"2012","journal-title":"J Res Med Sci"},{"key":"2020050713014887000_102.8.1077.7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.exer.2014.03.005","article-title":"Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy","volume":"122","author":"Wisniewska-Kruk","year":"2014","journal-title":"Exp Eye Res"},{"key":"2020050713014887000_102.8.1077.8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.exer.2014.03.006","article-title":"Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model","volume":"122","author":"Morera","year":"2014","journal-title":"Exp Eye Res"},{"key":"2020050713014887000_102.8.1077.9","doi-asserted-by":"crossref","unstructured":"Smith JM , Steel DH . Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2015:CD008214.doi:10.1002\/14651858.CD008214.pub3","DOI":"10.1002\/14651858.CD008214.pub3"},{"key":"2020050713014887000_102.8.1077.10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3928\/23258160-20141118-06","article-title":"A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy","volume":"45","author":"Pakzad-Vaezi","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2020050713014887000_102.8.1077.11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000000723","article-title":"Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"35","author":"Simunovic","year":"2015","journal-title":"Retina"},{"key":"2020050713014887000_102.8.1077.12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2013.02.008","article-title":"Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials","volume":"156","author":"Zhang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"2020050713014887000_102.8.1077.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.189514"},{"key":"2020050713014887000_102.8.1077.14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/IAE.0000000000000900","article-title":"Intravitreal conbercept (kh902) for surgical treatment of severe proliferative diabetic retinopathy","volume":"36","author":"Su","year":"2016","journal-title":"Retina"},{"key":"2020050713014887000_102.8.1077.15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/112067211002000604","article-title":"Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy","volume":"20","author":"Hern\u00e1ndez-Da Mota","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"2020050713014887000_102.8.1077.16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/eye.2017.75","article-title":"Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)","volume":"31","author":"Comyn","year":"2017","journal-title":"Eye"},{"key":"2020050713014887000_102.8.1077.17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"key":"2020050713014887000_102.8.1077.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.03.036"},{"key":"2020050713014887000_102.8.1077.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"2020050713014887000_102.8.1077.20","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181b1c99f"},{"key":"2020050713014887000_102.8.1077.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2020050713014887000_102.8.1077.22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611","article-title":"Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1","volume":"130","author":"Sohn","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"2020050713014887000_102.8.1077.23","first-page":"1","article-title":"Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1\u03b1","volume":"18","author":"Han","year":"2012","journal-title":"Mol Vis"},{"key":"2020050713014887000_102.8.1077.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1303-3"},{"key":"2020050713014887000_102.8.1077.25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/112067210901900526","article-title":"Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy","volume":"19","author":"Modarres","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"2020050713014887000_102.8.1077.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.001"},{"key":"2020050713014887000_102.8.1077.27","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.151233"},{"key":"2020050713014887000_102.8.1077.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0774-y"},{"key":"2020050713014887000_102.8.1077.29","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301005"},{"key":"2020050713014887000_102.8.1077.30","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.127142"},{"key":"2020050713014887000_102.8.1077.31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0161-6420(83)34540-1","article-title":"Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications","volume":"90","author":"Schachat","year":"1983","journal-title":"Ophthalmology"},{"key":"2020050713014887000_102.8.1077.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.047"},{"key":"2020050713014887000_102.8.1077.33","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.062638"},{"key":"2020050713014887000_102.8.1077.34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0161-6420(89)32686-8","article-title":"Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study","volume":"96","author":"Packer","year":"1989","journal-title":"Ophthalmology"},{"key":"2020050713014887000_102.8.1077.35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0161-6420(89)32649-2","article-title":"Hemostatic effects of air versus fluid in diabetic vitrectomy","volume":"96","author":"Joondeph","year":"1989","journal-title":"Ophthalmology"},{"key":"2020050713014887000_102.8.1077.36","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1990.01070060143065"},{"key":"2020050713014887000_102.8.1077.37","first-page":"1109","article-title":"ERK1\/2\/COX-2\/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes","volume":"20","author":"Li","year":"2014","journal-title":"Mol Vis"},{"key":"2020050713014887000_102.8.1077.38","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000233327.68433.02"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:56:31Z","timestamp":1601110591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311344"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311344","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}